Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Instagram Outage Disrupts Thousands of U.S. Users 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
CORALVILLE, Iowa, Aug. 03, 2017 -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canaccord Genuity 37th Annual Growth Conference being held August 9-10, 2017, at the InterContinental Boston Hotel.
Details of KemPharm's presentation are as follows:
| Date: | Thursday, August 10, 2017 | |||||
| Time: | 2:00 PM (ET) | |||||
| Location: | InterContinental Boston Hotel, 510 Atlantic Ave., Boston, MA 02210 | |||||
| Room: | The New York Room |
The presentation will be webcast and available on the Investor Relations section of the Company's website at http://investors.kempharm.com/.
About KemPharm
KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its LAT™ (Ligand Activated Therapy) platform technology. KemPharm utilizes its LAT™ platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, ADHD and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release profiles for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.
Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664 [email protected] [email protected] Media Contact: Daniel L. Cohen Executive VP, Government and Public Relations KemPharm, Inc. 202-329-1825 [email protected]
